Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1995 Feb 4;310(6975):285–288. doi: 10.1136/bmj.310.6975.285

Spread of bloodborne viruses among Australian prison entrants.

N Crofts 1, T Stewart 1, P Hearne 1, X Y Ping 1, A M Breshkin 1, S A Locarnini 1
PMCID: PMC2548691  PMID: 7866168

Abstract

OBJECTIVES--To assess spread of bloodborne viruses among prison entrants in Victoria, Australia. DESIGN--Voluntary confidential testing of all prison entrants for markers of exposure to bloodborne viruses with collection of minimal data on demography and risk factors over 12 months. SETTING--Her Majesty's Prisons, Pentridge and Fairlea, Victoria, Australia. SUBJECTS--3429 male and 198 female prison entrants (> 99% of all prison entrants); 344 entered prison and were tested more than once. MAIN OUTCOME MEASURES--Prevalence and incidence of antibodies to HIV, hepatitis B, and hepatitis C viruses, and minimal data on risk factors. RESULTS--1562 (46%) gave a history of use of injected drugs, 1171 (33%) had antibody to hepatitis B core antigen, 1418 (39%) were anti-hepatitis C positive including 914 (64%) of the men who injected drugs, 91 (2.5%) were positive for hepatitis B surface antigen, and 17 (0.47%) were positive for antibody to HIV. Incidence rates for infection with hepatitis B and C virus were 12.6 and 18.3 per 100 person years, respectively; in men who injected drugs and were aged less than 30 years (29% of all prison entrants) these were 21 and 41 per 100 person years. Seroconversion to hepatitis B or C was associated with young age and shorter stay in prison. Only 5% of those who were not immune to hepatitis B reported hepatitis B immunisation. CONCLUSIONS--Hepatitis B and C are spreading rapidly through some populations of injecting drug users in Victoria, particularly among men aged less than 30 years at risk of imprisonment in whom rates of spread are extreme; this group constitutes a sizeable at risk population for spread of HIV. This spread is occurring in a context of integrated harm reduction measures outside prisons for prevention of viral spread but few programmes within or on transition from prisons; it poses an urgent challenge to these programmes.

Full text

PDF
285

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayas J. M., Bruguera M., Martin V., Vidal J., Rodes J., Salleras L. Y. Hepatitis B vaccination in prisons: the Catalonian experience. Vaccine. 1993 Nov;11(14):1441–1444. doi: 10.1016/0264-410x(93)90174-v. [DOI] [PubMed] [Google Scholar]
  2. Bell J., Fernandes D., Batey R. Heroin users seeking methadone treatment. Med J Aust. 1990 Apr 2;152(7):361–364. [PubMed] [Google Scholar]
  3. Bird A. G., Gore S. M., Jolliffe D. W., Burns S. M. Anonymous HIV surveillance in Saughton Prison, Edinburgh. AIDS. 1992 Jul;6(7):725–733. doi: 10.1097/00002030-199207000-00017. [DOI] [PubMed] [Google Scholar]
  4. Christie B. HIV outbreak investigated in Scottish jail. BMJ. 1993 Jul 17;307(6897):151–152. [PubMed] [Google Scholar]
  5. Crofts N., Hopper J. L., Bowden D. S., Breschkin A. M., Milner R., Locarnini S. A. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust. 1993 Aug 16;159(4):237–241. doi: 10.5694/j.1326-5377.1993.tb137822.x. [DOI] [PubMed] [Google Scholar]
  6. Decker M. D., Vaughn W. K., Brodie J. S., Hutcheson R. H., Jr, Schaffner W. The incidence of hepatitis B in Tennessee prisoners. J Infect Dis. 1985 Jul;152(1):214–217. doi: 10.1093/infdis/152.1.214. [DOI] [PubMed] [Google Scholar]
  7. Donoghoe M. C., Stimson G. V., Dolan K. A. Sexual behaviour of injecting drug users and associated risks of HIV infection for non-injecting sexual partners. AIDS Care. 1989;1(1):51–58. doi: 10.1080/09540128908260235. [DOI] [PubMed] [Google Scholar]
  8. Gaughwin M. D., Douglas R. M., Liew C., Davies L., Mylvaganam A., Treffke H., Edwards J., Ali R. HIV prevalence and risk behaviours for HIV transmission in South Australian prisons. AIDS. 1991 Jul;5(7):845–851. doi: 10.1097/00002030-199107000-00008. [DOI] [PubMed] [Google Scholar]
  9. Gaughwin M. D., Douglas R. M., Liew C., Davies L., Mylvaganam A., Treffke H., Edwards J., Ali R. HIV prevalence and risk behaviours for HIV transmission in South Australian prisons. AIDS. 1991 Jul;5(7):845–851. doi: 10.1097/00002030-199107000-00008. [DOI] [PubMed] [Google Scholar]
  10. Gore S. M., Bird A. G. No escape: HIV transmission in jail. BMJ. 1993 Jul 17;307(6897):147–148. doi: 10.1136/bmj.307.6897.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Greenland S., Robins J. M. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985 Mar;41(1):55–68. [PubMed] [Google Scholar]
  12. Hahn R. A., Onorato I. M., Jones T. S., Dougherty J. Prevalence of HIV infection among intravenous drug users in the United States. JAMA. 1989 May 12;261(18):2677–2684. [PubMed] [Google Scholar]
  13. Holsen D. S., Harthug S., Myrmel H. Prevalence of antibodies to hepatitis C virus and association with intravenous drug abuse and tattooing in a national prison in Norway. Eur J Clin Microbiol Infect Dis. 1993 Sep;12(9):673–676. doi: 10.1007/BF02009378. [DOI] [PubMed] [Google Scholar]
  14. Kaldor J., Elford J., Wodak A., Crofts J. N., Kidd S. HIV prevalence among IDUs in Australia: a methodological review. Drug Alcohol Rev. 1993;12(2):175–184. doi: 10.1080/09595239300185611. [DOI] [PubMed] [Google Scholar]
  15. Okamoto H., Munekata E., Tsuda F., Takahashi K., Yotsumoto S., Tanaka T., Tachibana K., Akahane Y., Sugai Y., Miyakawa Y. Enzyme-linked immunosorbent assay for antibodies against the capsid protein of hepatitis C virus with a synthetic oligopeptide. Jpn J Exp Med. 1990 Aug;60(4):223–233. [PubMed] [Google Scholar]
  16. Skidmore C. A., Robertson J. R., Robertson A. A., Elton R. A. After the epidemic: follow up study of HIV seroprevalence and changing patterns of drug use. BMJ. 1990 Jan 27;300(6719):219–223. doi: 10.1136/bmj.300.6719.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sugitani M., Inchauspé G., Shindo M., Prince A. M. Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet. 1992 Apr 25;339(8800):1018–1019. doi: 10.1016/0140-6736(92)90538-e. [DOI] [PubMed] [Google Scholar]
  18. Thompson S. C., Stevenson E., Wilby R., Crofts N. Hepatitis B infection in Victoria 1992: time to review the high-risk vaccination strategy. Med J Aust. 1993 Oct 18;159(8):562–563. doi: 10.5694/j.1326-5377.1993.tb138023.x. [DOI] [PubMed] [Google Scholar]
  19. Vlahov D., Brewer T. F., Castro K. G., Narkunas J. P., Salive M. E., Ullrich J., Muñoz A. Prevalence of antibody to HIV-1 among entrants to US correctional facilities. JAMA. 1991 Mar 6;265(9):1129–1132. [PubMed] [Google Scholar]
  20. Watson P. G., Watts J. R., Nelson M. The incidence of Australia antigen and antibody in male prisoners of two Sydney penitentiaries. Med J Aust. 1973 Sep 1;2(9):421–423. doi: 10.5694/j.1326-5377.1973.tb115203.x. [DOI] [PubMed] [Google Scholar]
  21. Wolk J., Wodak A., Morlet A., Guinan J. J., Gold J. HIV-related risk-taking behaviour, knowledge and serostatus of intravenous drug users in Sydney. Med J Aust. 1990 May 7;152(9):453–458. doi: 10.5694/j.1326-5377.1990.tb125302.x. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES